NCT06945146 2025-04-25
CAP
Eulji University Hospital
Completed
Clinical Trials
8 trialsNCT02272998 2025-03-24
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01935336 2022-02-11
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
Phase 2 Completed
NCT02265341 2020-11-25
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Mayo Clinic
Phase 2 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01813734 2019-12-24
Ponatinib in Advanced NSCLC w/ RET Translocations
Massachusetts General Hospital
Phase 2 Completed
NCT02478164 2018-07-24
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02981784 2016-12-05
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
Hospices Civils de Lyon
Completed